Look back at pharma news in week to June 15

17 June 2018

By Barbara Obstoj-Cardwell. Editor

Last week, regulatory news featured, with the announcement that the US Food and Drug Administration has approved AbbVie and Roche’s Venclexta in leukemia and lymphoma indications. Also attracting attention was China’s approval of the first immuno-oncology drug, Bristol-Myers Squibb’s Opdivo. New clinical trial results were in focus, with yet another Alzheimer’s drug failure, this one for Eli Lilly and AstraZeneca’s candidate lanabecestat, and Vical’s herpes simplex virus vaccine disappointment in Phase II studies, but the company still has a positive pipeline. However, there was a positive surprise from Israel’s Galmed trial with Aramchol in non-alcoholic steatohepatitis (NASH).

FDA grants full approval for AbbVie and Roche’s venetoclax for CLL and SLL

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK